Category: New products
-
Prenatal Genome Edits Prevent Inherited Liver Disorder
Research with lab mice shows prenatal genome editing with techniques including Crispr can correct an inherited defect associated with a fatal congenital liver disorder.
-
Trials to Test Stem Cell Treatments for Eye Injuries
A series of clinical trials are planned to test the use of adult stem cells to treat injuries to the eyes that lead to vision loss.
-
Artificial Pancreas Controls Type 1 Diabetes Better Than Insulin Pump Alone
A clinical trial shows a closed-loop algorithm-controlled artificial pancreas system helps people with type 1 diabetes better control their blood sugar levels than a glucose sensor and insulin pump system alone.
-
Jet Fuel from Carbon Waste Powers Virgin Atlantic Flight
A Virgin Atlantic flight arriving earlier today from Orlando, Florida to London’s Gatwick airport is the first to use a biofuel made from fermented carbon-rich industrial waste gases.
-
Human Antibodies Devised for Snakebite Treatment
An academic-industry team in Europe and Central America assembled a group of human antibodies that protects lab mice against venomous toxins from a dangerous African snake.
-
Protein Delivered with Gold Nanoparticles Helps Fix Muscle Injuries
A bioengineering lab at Harvard University devised a technique using gold nanoscale particles to deliver a protein to reduce inflammation from muscle injuries in lab mice.
-
Genome Editing Offers Marketable Wild Tomato
The groundcherry, a wild tomato plant that its devotees say has a delicious and unusual flavor, could be grown on farms for sale to consumers thanks to a genome editing project at two New York research institutes.
-
Wireless Solar Power, Data Transmission Designed for IoT
A process for capturing light to power Internet of Things, or IoT devices, is shown to use the same solar cells to transmit data over an IoT system.
-
Antibody Combination Shown to Suppress HIV
Results from a small-scale clinical trial show a combination of antibodies can suppress the HIV virus for many weeks after stopping antiretroviral therapy.
-
$29.5M Funding Raised for Sinus Drug Delivery Company
A company developing a drug delivery technology to treat chronic sinus conditions is raising $29.5 million in its second venture financing round.